BioCardia
BCDA1.0904.81% ( +0.050 )
BioCardia (BCDA)
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in th...
- Open
- 1.060
- High
- 1.090
- Low
- 1.040
- Prev. Close
- 1.040
- Volume
- 148.93K
- Turnover
- 158.83K
- Avg Price
- 1.066
- Bid/Ask Ratio
- -33.33%
- Amplitude
- 4.81%
- 52wk High
- 1.800
- Volume Ratio
- 0.65
- Turnover Ratio
- 1.21%
- 52wk Low
- 0.750
- Float Mkt Cap
- 13.36M
- Market CapUSD
- 16.50M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.485
- EPSDynamic
- -0.512
- EPSStatic
- --
- BVPS
- 0.18
- P/B
- 6.11
- Circulating Supply
- 12.26M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 15.14M
- Min lot size
- 1
- Currency
- USD
BioCardia Analyst Rating
View moreForecast & Rating
Aug 24, 2026Price forecast
$15.501322.02%
Forecast & RatingStrong buy
2analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT ·
BioCardia files revised FDA De Novo pre-submission for Helix catheter clearance
- PUBT ·
BioCardia CEO Peter Altman acquires $1,030 in common shares
- PUBT ·
BioCardia CEO Peter Altman acquires common shares worth $1,995
- StockTitan ·
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission | BCDA Stock News
